Author: Benzinga Newsdesk | November 05, 2025 07:37am
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.78 percent. This is a 62.92 percent increase over losses of $(0.89) per share from the same period last year.